• 1
    Breast Cancer Task Force Treatment Committee, National Cancer Institute. Report from the combination chemotherapy trials working group. U.S. Department of Health, Education and Welfare. DHEW Publication No. (NIH) 77–1192, 1977.
  • 2
    Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Reubens RD. Assessment of response to therapy in advanced breast cancer. Cancer 1977; 39:12891294.
  • 3
    ICD-O. International Classification of Disease for Oncology. 1st Ed. 1976. World Health Organization, Geneva.
  • 4
    Karnofsky DA, Abelman WH, Craver LF, et al. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1:634656.
  • 5
    Moertel CG, Hanley JA: The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 1976; 38:388394.
  • 6
    UICC, TNM. Classification of Malignant Tumors, 3rd ed. International Union Against Cancer, Geneva, 1978.
  • 7
    WHO Handbook for Standardized Cancer Registries. WHO Offset publication No. 25, World Health Organization, Geneva, 1976.
  • 8
    WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset publication No. 48, World Health Organization, Geneva, 1979.
  • 9
    Zubrod, CG, Schneiderman MA, Frei E, et al. Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 1960; 11:733.